ArticleCureus2026
Rapidly Progressive Primary Ovarian Malignant Perivascular Epithelioid Cell Tumor.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Perivascular epithelioid cell tumor (PEComa) is a rare mesenchymal neoplasm characterized by a unique dual differentiation toward smooth muscle and melanocytic lineages. While PEComas can arise in various gynecologic organs, primary malignant ovarian PEComa is exceptionally rare and shows a wide spectrum of clinical behaviors. We report a case of a rapidly progressive primary ovarian malignant PEComa with an extremely poor prognosis. A 73-year-old woman presented with fever and malaise. A CT scan incidentally revealed a left ovarian tumor, for which she was referred to our department. Tumor markers were within normal limits, but MRI and CT suggested a left ovarian malignancy. A total hysterectomy and bilateral salpingo-oophorectomy were performed. Pathological examination revealed a 9 cm solid mass with necrosis, cytologic atypia, high mitotic activity (14/HPF), and vascular invasion. Immunohistochemistry was positive for both melanocytic markers (MelanA, HMB45) and the myogenic marker desmin, leading to a diagnosis of malignant PEComa. Based on the presence of multiple worrisome features, the tumor was classified as malignant according to established criteria. Despite the absence of distant metastasis at initial imaging and surgery, the patient was offered adjuvant therapy but declined. She developed local recurrence and lung metastasis 72 days after surgery and died 169 days after surgery. This case highlights the clinical significance of a primary ovarian malignant PEComa and the importance of recognizing its potential for rapid and aggressive progression. The finding that multiple pathological risk factors predicted a poor clinical outcome reinforces the need for accurate diagnosis and prompt consideration of systemic therapy, such as mTOR inhibitors, in addition to surgical resection. This report contributes valuable insights into the clinical course of this rare tumor, underscoring the necessity of close follow-up and multidisciplinary management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.